30825-34-4

Basic information

• Product Name: 3-AMINO-5-(TRIFLUOROMETHYL)BENZONITRILE
• Synonyms: CIS (+) HYDROXY LACTAM;3-amino-5-(trifluoromethyl)benzonitrile;3-AMino-5-cyanobenzotrifluoride;trans-2,3-Dihydro-3-hydroxy-2-(4-Methoxyphenyl)-1,5-benzothiazepin-4(5H)-one;(2R,3S)-3-Hydroxy-2-(4-Methoxyphenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one;Moxifloxacin Impurity V
• CAS NO: 30825-34-4
• Molecular Formula: C₁₆H₁₅NO₃S
• Molecular Weight: 186.13
• Mol File: 30825-34-4.mol

Chemical Properties

• Boiling Point: 279.316 °C at 760 mmHg
• Flash Point: 122.726 °C
• Appearance: /
• Density: 1.371 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.5
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 12.37±0.40(Predicted)
• CAS DataBase Reference: 3-AMINO-5-(TRIFLUOROMETHYL)BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-5-(TRIFLUOROMETHYL)BENZONITRILE(30825-34-4)
• EPA Substance Registry System: 3-AMINO-5-(TRIFLUOROMETHYL)BENZONITRILE(30825-34-4)

Safety Data

• Hazardous Substances Data: 30825-34-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-AMINO-5-(TRIFLUOROMETHYL)BENZONITRILE is used as a research reagent for organic synthesis. Its unique structure allows it to be a valuable building block in the development of various organic compounds, particularly those with pharmaceutical or chemical applications.
Used in Chemical Processes:
In addition to its role in organic synthesis, 3-AMINO-5-(TRIFLUOROMETHYL)BENZONITRILE is also utilized in other chemical processes. Its reactivity and functional groups make it a versatile compound for use in the development of new materials, catalysts, and other chemical products.

InChI:InChI=1/C8H5F3N2/c9-8(10,11)6-1-5(4-12)2-7(13)3-6/h1-3H,13H2

Upstream product

• 30193-57-8 (+/-)-(R*,R*)-β-<(2-aminophenyl)thio>-α-hydroxy-4-methoxybenzenepropanoic acid 
• 96125-49-4 methyl trans-3-(4-methoxyphenyl)glycidate 
• 137-07-5 2-amino-benzenethiol 
• 42245-42-1 methyl (2-RS,3-SR)-2,3-epoxy-3-(4-methoxyphenyl)propanoate 
• 30193-56-7 (+/-)-(R*,R*)-β-[(2-aminophenyl)thio]-α-hydroxy-4-methoxybenzenepropanoic acid, methyl ester 
• 123-11-5 4-methoxy-benzaldehyde 
• 154076-93-4 ethyl (Z)-2-(2-methoxyethoxy)methoxy-3-(4-methoxyphenyl)-2-propenoate 
• 30067-00-6 (2RS,3SR)-2-hydroxy-3-(4-methoxy-phenyl)-3-(2-nitro-phenylsulfanyl)-propionic acid methyl ester 
• 30193-56-7 (2RS,3RS)-3-(2'-aminophenylthio)-2-hydroxy-3-(4''-methoxyphenyl)-propionic acid methyl ester 
• 30193-57-8 erythro-(-)-3-((2-aminophenyl)thio)-2-hydroxy-3-(4-methoxyphenyl)propionic acid 
• 30193-57-8 erythro-(+)-3-((2-aminophenyl)thio)-2-hydroxy-3-(4-methoxyphenyl)propionic acid 

Downstream Products

• 81353-09-5 3c-hydroxy-2r-(4-methoxy-phenyl)-5-(2-methylamino-ethyl)-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one 
• 97801-78-0 3-acetoxy-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one 
• 23515-44-8 5-(2-dimethylamino-ethyl)-3c-hydroxy-2r-(4-methoxy-phenyl)-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one 
• 42399-40-6 O-desacetyldiltiazem 
• 42399-53-1 (2RS,3RS)-cis-2,3-dihydro-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one 
• 42399-49-5 (2S,3S)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one 
• 132830-17-2 trans-(2R,3S)-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one 
• 97801-79-1 2-(4-methoxyphenyl)-1,5-benzothiazepine-3,4(2H,5H)-dione 
• 132830-16-1 (-)-trans-(2S,3R)-2,3-dihydro-3-hydroxy-2-(4'-methoxyphenyl)-1,5-benzothiazepin-4-[5H]-one 
• 91926-67-9 (2S,3R)-5-<2-(dimethylamino)ethyl>-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one 
• 111188-70-6 (2S,3R)-3-acetoxy-5-<2-(dimethylamino)ethyl>-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one 
• 91926-66-8 (2R,3S)-5-<2-(dimethylamino)ethyl>-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one 
• 111188-71-7 (2R,3S)-3-acetoxy-5-<2-(dimethylamino)ethyl>-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one 
• 128488-33-5 (2R,3R)-2-Benzyl-5-(2-dimethylamino-ethyl)-3-hydroxy-2-(4-methoxy-phenyl)-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one 

Relevant articles and documents

Optical resolution of a 1,5-benzothiazepine derivative, a synthetic intermediate of diltiazem, by preferential crystallization and diastereomeric salt formation

Practical preparation methods of an optically active intermediate of diltiazem, (+)-(2S,3S)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2- (4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one [(+)-7], have been developed by the use of physicochemical and chemical resolutions. 1) The salt of (+)-7 with 3-amino-4-hydroxy-benzenesulfonic acid (AHS), was found to exist as a conglomerate and could be reproducibly resolved into (+)-7·AHS and (-)- 7·AHS of 94-98% ee by a preferential crystallization procedure. 2) (+)- (1R)-3-Bromocamphor-9-sulfonic acid [(+)-BCS] was found to be an efficient resolving agent for (±)-7 and the diastereomeric resolution provided (+)- 7·(+)-BCS·2H2O salt in >43% yield and >97% ee by fractional crystallization. It is presumed that the crystal water of (+)-7·(+)- BCS·2H2O plays an important role in the selective crystallization during this efficient resolution.

A microwave synthesis of the cis and trans isomers of 3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one : The influence of solvent and power output on the diastereoselectivity

A diastereoselective one-pot synthesis and the trans- and cis-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H) -one nucleus, a key intermediate in the preparation of the calcium channel blocker Diltiazem, is carried out under microwave irradiation in an open vessel. Control of the diastereoselectivity is achieved by varying the reaction time and power output as well as the nature of the solvent.

cis-(±)-5-[2- (Dimethylamino)ethyl]-3-hydroxy-2-(4- methoxyphenyl )-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-one

The title compound, C20H24N2O3S, is a drug intermediate of diltiazem. The molecule is stabilized by covalent bonding and weak hydrogen bonding, and the crystal packing is stabilized by hydrogen bonding. The seven-membered ring is distorted showing a twist-boat conformation. The methoxyphenyl and hydroxy groups are cis oriented with respect to one another, with the phenyl ring in an axial position. Intermolecular hydrogen bonding produces dimers in the crystal.

Enantiomer associations in the crystal structures of racemic and (2S,3R)-(-)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)- one

The crystal structures of racemic and (2S,3R)-(-)-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)- one (C16H15NO3S) have been determined in order to compare the interactions between molecules of the same and opposite chirality. The enantiomeric associations observed in these two crystal structures are analysed, relating the differences to those found in the equivalent diastereomers, (2R, 3R) and/or (2S, 3S). Single-crystal X-ray diffraction data were collected at low temperature with Cu Kα radiation (λ = 1.54184 A). Optically active: monoclinic, space group C2, with a = 24.726(3), b = 5.2426(5), c =12.0726(12) A, β - 112.979(9)°, V = 1440.8(5) A3, Z = 4, Dx= 1.389 g cm-3, μ = 20.35 cm-1, the refinement on 2918 observed reflections gave R=0.0271. Racemic: monoclinic, space group P21/n, with a = 13.308(3), b = 4.8474(8), c = 22.130(4) A, β = 91.782(14), V= 1426.9(5) A3, Z=4, Dx= 1.403 g cm-3, μ= 20.54 cm-1, refined to R = 0.0318 for 2753 observed reflections. An intramolecular hydrogen bond between the hydroxy and carbonyl groups appears to stabilize the benzothiazepinone ring in the (P,2S,3R) boat conformation with the hydroxy and methoxyphenyl substituents in equatorial positions. In both crystal structures two N-H...O hydrogen bonds connect the molecules into dimers. In the optically active compound the two molecules are related by a twofold axis, in the racemate by an inversion centre. The racemate contains an additional hydrogen bond which is reflected by its higher melting enthalpy compared with the optically active compound. The difference in the chiral discrimination in the solutions of the cis-and trans-diastereomers does not appear to have its origin in the strong (O-H...O, N-H...O) hydrogen bonds, but rather in the weak (C-H...O) interactions. Acta Chemica Scandinavica 1996.

Stereoselective addition of 2-aminothiophenol to α-alkoxycinnamic acid derivatives - Alternative synthesis of (±)-diltiazem

A stereocontrolled synthesis of (±)-diltiazem by applying nucleophilic addition of 2-aminothiophenol to α-alkoxycinnamic acid derivatives is described.

ENANTIOMER-ASSOCIATIONS INFLUENCING CHEMICAL REACTIVITY.

A comparative study for a ring-closure reaction in solution, melt and solid state is reported.The different behaviour of the different enantio-composition is explained on the basis of enantiomer-associate formation.

Reaction of 3-Phenylglycidic Esters. III. Reaction of cis-3-Arylglycidic Esters with Various Thiophenols

The reaction of the cis-3-arylglycidic esters 2 and 10 with thiophenols (3) has been investigated.The reactivity and stereoselectivity of the oxirane ring-opening of these cis-glycidic esters were lower than those of the trans-analogues (1 and 9).These tendencies were more apparent in the 4-MeO derivative (2).On the other hand, the tin-catalyzed reaction of 2 with 3a was highly stereospecific and afforded the cis-opening products (5a).Keywords - cis-3-arylglycidic ester; thiophenol; oxirane ring-opening; tin catalyst; stereoselectivity